UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36374 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 74-29 ...

Summary of Actinium Pharmaceuticals Conference Call Company Overview - **Company**: Actinium Pharmaceuticals - **Industry**: Biotechnology, specifically focused on targeted radiotherapy for cancer treatment - **Stock Symbol**: ATNM on NYSE American Key Points and Arguments 1. **Targeted Radiotherapy**: Actinium Pharmaceuticals specializes in linking radiation to targeting agents aimed at various cancer targets, utilizing both beta and alpha emitters for treatment across blood cancers and solid tumors [3][4] 2. **Pipeline Overview**: The company has a robust pipeline with over 230 patents, focusing on three key disease areas: hematology (blood cancers), solid tumors, and targeted conditioning for cell and gene therapy [5] 3. **Lead Program - Actemab A**: Actemab A is advancing towards a Phase 2/3 trial, targeting CD33 in blood cancers, particularly acute myeloid leukemia (AML). The drug has shown promising results in combination with chemotherapy [10][12] 4. **Clinical Trials**: Actemab A has been studied in approximately 150 patients across six clinical trials, demonstrating a high overall response rate of over 50% in high-risk patient groups [15][16] 5. **Market Opportunities**: The potential market for Actemab A exceeds 100,000 patients in the US and top five countries, with mutation-agnostic properties making it a versatile treatment option [19][20] 6. **Solid Tumor Expansion**: The company is exploring Actemab A's application in solid tumors, particularly in combination with PD-1 checkpoint inhibitors for head and neck and non-small cell lung cancer [21][24] 7. **New Program - ATNM-400**: A next-generation prostate cancer therapeutic candidate, ATNM-400, is being developed to address a large patient population, showing more potency than existing therapies like Pluvicto [7][25] 8. **Manufacturing Capabilities**: Actinium is focused on establishing in-house manufacturing capabilities for radioisotopes, particularly Actinium-225, to support future clinical trials [9][34] 9. **IMMab ACT Program**: This program targets CD45 for CAR T therapy and sickle cell disease, with promising preclinical data indicating low toxicity and effective outcomes in heavily pretreated patients [28][30] 10. **Financial Outlook**: The company has a cash runway extending into mid-2027, allowing for the advancement of multiple pipeline assets and potential partnerships [34][36] Additional Important Content - **Collaboration with NCI**: Actinium has entered a cooperative research and development agreement with the National Cancer Institute (NCI) to co-develop Actemab A, enhancing its clinical research capabilities [6][18] - **Survival Outcomes**: The trial results indicated a median overall survival of 18 months for patients treated with Actemab A, significantly higher than typical outcomes for similar patient groups [17] - **Regulatory Alignment**: The company has aligned with the FDA on the Phase 2/3 study design for Actemab A, indicating a structured approach to clinical development [18][36] - **Market Growth**: The CAR T therapy market has grown to over $4 billion in annual sales, with significant growth expected in the cell and gene therapy market [32] This summary encapsulates the critical insights from the conference call, highlighting Actinium Pharmaceuticals' strategic focus on targeted radiotherapy and its promising pipeline in the oncology space.

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Actinium Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on May 27, 2025 [1]. Group 1: Class Action Details - Investors who purchased Actinium securities between October 31, 2022, and August 2, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that during the Class Period, Actinium made false or misleading statements regarding its Iomab-B Biologics License Application, which may not meet FDA guidelines [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in securities class action settlements [4].

Core Viewpoint - A class action securities lawsuit has been filed against Actinium Pharmaceuticals, alleging securities fraud that negatively impacted investors between October 31, 2022, and August 2, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the Phase 3 Sierra trial data, which was unlikely to meet FDA guidelines for the approval of the targeted radiotherapy, Iomab-B BLA [2]. - It is alleged that additional analyses provided to the FDA, which suggested improved Overall Survival, were also unlikely to satisfy FDA requirements, leading to a probable refusal to review the Iomab-B BLA [2]. - The lawsuit contends that the defendants' positive statements about the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until May 27, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]. - The firm has over 70 employees dedicated to serving clients in complex securities litigation [4].

Core Viewpoint - Actinium Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between October 31, 2022, and August 2, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the Phase 3 Sierra trial data, which was unlikely to meet FDA guidelines for the approval of the targeted radiotherapy, Iomab-B BLA [2]. - Additional analyses provided to the FDA, which were intended to show improved Overall Survival, were also unlikely to satisfy FDA requirements for the Iomab-B BLA [2]. - The lawsuit suggests that the FDA would likely refuse to review the Iomab-B BLA or that the application, in its current form, was unlikely to be approved [2]. - Defendants' positive statements about the Company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until May 27, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Actinium Pharmaceuticals, Inc. regarding a class action lawsuit due to alleged misleading statements related to the company's drug approval process [1][2]. Group 1: Allegations - The complaint alleges that during the class period from October 31, 2022, to August 2, 2024, the defendants made materially false and misleading statements regarding the Phase 3 Sierra trial data [2]. - It is claimed that the data from the Sierra trial was unlikely to meet FDA guidelines for the approval of the targeted radiotherapy, Iomab-B BLA [2]. - The additional analyses provided to the FDA to support the Sierra trial's poor overall survival data were also unlikely to satisfy FDA requirements [2]. - As a result of these issues, the FDA was expected to refuse to review the Iomab-B BLA or find it unlikely to approve the application in its current form [2]. - The defendants' positive statements about the company's business and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is May 27, 2025, and they are encouraged to register promptly [3]. - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Actinium Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on May 26, 2025 [1] Group 1: Class Action Details - Investors who purchased Actinium securities between October 31, 2022, and August 2, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - To serve as lead plaintiff, individuals must file a motion with the Court by May 26, 2025 [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [4] Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Actinium made false or misleading statements regarding its Iomab-B Biologics License Application (BLA) and the likelihood of FDA approval [5] - Specific claims include that data from the Sierra Trial was unlikely to meet FDA guidelines, and as a result, the FDA might refuse to review the BLA or deny approval [5] - The lawsuit asserts that the defendants' positive statements about Actinium's business and prospects were materially misleading [5]

Core Viewpoint - A federal securities class action has been filed against Actinium Pharmaceuticals, with a deadline for investors to seek lead plaintiff status by May 27, 2025, related to securities acquired between October 31, 2022, and August 2, 2024 [1]. Group 1: Company Developments - On August 5, 2024, Actinium announced a regulatory update regarding its Biologics License Application (BLA) for lomab-B, revealing that the FDA required an additional clinical study to support the BLA filing [3]. - Following the announcement, Actinium's share price fell by $3.69, or approximately 59%, from $6.17 on August 2, 2024, to $2.48 on August 5, 2024 [3]. Group 2: Legal Allegations - The complaint alleges that during the Class Period, Actinium misled the market regarding the likelihood of its BLA data meeting FDA guidelines for acceptance and approval [4].

Core Viewpoint - Actinium Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between October 31, 2022, and August 2, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the Phase 3 Sierra trial data, which was unlikely to meet FDA guidelines for the approval of the targeted radiotherapy, Iomab-B BLA [2]. - Additional analyses provided to the FDA, which suggested improved Overall Survival, were also claimed to be insufficient to satisfy FDA requirements for Iomab-B BLA approval [2]. - The lawsuit indicates that the FDA would likely refuse to review the Iomab-B BLA or that the application, in its current form, was unlikely to be approved [2]. - Defendants' positive statements about the Company's business and prospects were alleged to be materially misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses in Actinium during the specified timeframe have until May 27, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Actinium Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on May 26, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Actinium securities between October 31, 2022, and August 2, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The deadline to move the Court to serve as lead plaintiff is May 26, 2025, with the lead plaintiff acting on behalf of other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been ranked highly for securities class action settlements [4] Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Actinium made false or misleading statements regarding the likelihood of FDA approval for its Iomab-B Biologics License Application [5] - Specific claims include that data from the Sierra Trial was unlikely to meet FDA guidelines, and that positive statements made by Actinium were materially misleading [5]